Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Akoya Biosciences Inc (AKYA)

Akoya Biosciences Inc (AKYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,750
  • Shares Outstanding, K 49,386
  • Annual Sales, $ 96,630 K
  • Annual Income, $ -63,320 K
  • 60-Month Beta 1.52
  • Price/Sales 1.48
  • Price/Cash Flow N/A
  • Price/Book 4.38
Trade AKYA with:

Options Overview Details

View History
  • Implied Volatility 119.22% ( +6.19%)
  • Historical Volatility 108.58%
  • IV Percentile 89%
  • IV Rank 44.10%
  • IV High 268.49% on 04/29/24
  • IV Low 1.48% on 01/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 903
  • Open Int (30-Day) 899

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.28
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +50.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.65 +6.04%
on 05/16/24
4.65 -39.57%
on 05/10/24
-0.99 (-26.05%)
since 04/19/24
3-Month
2.65 +6.04%
on 05/16/24
6.31 -55.47%
on 03/04/24
-2.82 (-50.09%)
since 02/20/24
52-Week
2.65 +6.04%
on 05/16/24
8.80 -68.07%
on 06/16/23
-3.15 (-52.85%)
since 05/19/23

Most Recent Stories

More News
Stock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell Remarks

June S&P 500 E-Mini futures (ESM24) are up +0.02%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.03% this morning as investors geared up for crucial U.S. producer inflation data while also awaiting...

ESM24 : 5,332.50 (+0.01%)
NQM24 : 18,752.75 (-0.05%)
INCY : 57.19 (+0.16%)
INTC : 32.10 (+0.85%)
SQSP : 44.14 (+0.75%)
AMAT : 219.95 (+3.71%)
HD : 337.82 (-1.86%)
ALC.Z.IX : 79.980 (-1.06%)
DHER.D.DX : 30.910 (-2.49%)
RHM.D.DX : 528.800 (+3.16%)
FULC : 7.70 (+1.99%)
FOLD : 9.75 (+1.88%)
Why Shares of Akoya Biosciences Jumped on Tuesday

A rash of insider buying buoyed investor confidence in the medical instrument company.

AKYA : 2.81 (-1.40%)
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -6.52% and 5.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 2.81 (-1.40%)
CELU : 3.14 (+4.67%)
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 2.81 (-1.40%)
ACET : 1.6200 (+1.25%)
Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RAPT : 4.00 (-0.99%)
AKYA : 2.81 (-1.40%)
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 1.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 3.07 (+3.02%)
AKYA : 2.81 (-1.40%)
Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CERT : 16.36 (+1.74%)
AKYA : 2.81 (-1.40%)
Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

RXDX : 199.92 (+0.09%)
AKYA : 2.81 (-1.40%)
Will Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKYA : 2.81 (-1.40%)
ICPT : 19.00 (+0.21%)
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LGND : 86.63 (+0.66%)
AKYA : 2.81 (-1.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Akoya Biosciences Inc. offers comprehensive single-cell imaging solutions which allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. The company offer distinct solutions, the CODEX(R) and Phenoptics(TM)...

See More

Key Turning Points

3rd Resistance Point 3.08
2nd Resistance Point 3.02
1st Resistance Point 2.91
Last Price 2.81
1st Support Level 2.74
2nd Support Level 2.68
3rd Support Level 2.57

See More

52-Week High 8.80
Fibonacci 61.8% 6.45
Fibonacci 50% 5.73
Fibonacci 38.2% 5.00
Last Price 2.81
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar